Trident Lifeline Limited has submitted to the BSE the certificate statement of deviation for the quarter ended June 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Trident Lifeline has submitted a regulatory statement under SEBI LODR Regulation 32 confirming the status of IPO fund utilization for the quarter ended June 30, 2025. The company had raised Rs. 35.34 crore through its IPO in October 2022. Of this, Rs. 30.51 crore (about 86%) has been utilized with no deviation or variation reported. The breakup shows working capital needs are nearly fully met (Rs. 20.29 crore used out of Rs. 20.50 crore allocated), general corporate purpose is almost fully used (Rs. 6.70 crore out of Rs. 6.71 crore), and public issue expenses are completely utilized (Rs. 3 crore). However, only about 10% (Rs. 0.52 crore) of the Rs. 5.14 crore allocated for Product Registration in international markets has been used so far, leaving Rs. 4.62 crore pending. The auditor (A Bafna & Associates) certified no deviation, and the Audit Committee reviewed the statement on July 28, 2025.
This is a routine compliance filing that signals disciplined use of IPO proceeds with no misuse or deviation, which is positive for governance. However, the very low utilization in the international product registration objective (just 10% in nearly three years post-IPO) suggests slow progress on expansion plans, something retail investors should monitor as a potential risk to the company's stated growth roadmap.